Coronado Biosciences finishes funding, fills executive seats

Coronado Biosciences, a New York-based company focused on oncology drug development, has completed a financing series worth $21.6 million. The funds will be used to develop its acute myelogeous leukemia drug, CNDO-109. The company also announced that Glenn Cooper (executive chairman and acting CEO), Eric Rowinsky (vice chairman) and Gary Gemignani (executive VP, COO and CFO) have joined the company. Coronado release

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.